Formycon Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Stefan Glombitza

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	6.9yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.2yrs
Gemiddelde ambtstermijn bestuur	8.5yrs

Recente managementupdates

Recent updates

CEO

Stefan Glombitza (58 yo)

6.9yrs

Tenure

Dr. Stefan Glombitza has been the Chief Operating Officer and Member of Executive Board at Formycon AG since October 1, 2016 and is Chief Executive Officer from July 01, 2022. Dr. Glombitza has extensive e...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Stefan Glombitza	CEO, COO & Member of Executive Board	6.9yrs	geen gegevens	geen gegevens
Friedrich-Wilhelm Steinweg	Co-Founder	no data	geen gegevens	geen gegevens
Nicolas Combe	Co-Founder	no data	geen gegevens	geen gegevens
Enno Spillner	CFO & Member of Management Board	less than a year	geen gegevens	geen gegevens
Andreas Seidl	Chief Scientific Officer & Member of Executive Board	1.2yrs	geen gegevens	geen gegevens
Nicola Mikulcik	Chief Business Officer & Member of Executive Board	1.3yrs	geen gegevens	geen gegevens
Sabrina Muller	Senior Manager of Corporate Communications & Investor Relations	no data	geen gegevens	geen gegevens

1.2yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van FYBD wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.2 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Bernhard Hampl	Member of Advisory Board	9.5yrs	geen gegevens	geen gegevens
Gerhard Schaefer	Member of Advisory Board	9.8yrs	geen gegevens	geen gegevens
Olaf Stiller	Chairman of Supervisory Board	13.7yrs	geen gegevens	geen gegevens
Peter Wendeln	Deputy Chairman of Supervisory Board	13.7yrs	geen gegevens	geen gegevens
Johannes Buchner	Member of Advisory Board	7.6yrs	geen gegevens	geen gegevens
Thomas Siklosi	Member of Advisory Board	5.1yrs	geen gegevens	geen gegevens
Klaus Rohrig	Member of Supervisory Board	2.8yrs	geen gegevens	geen gegevens
Wolfgang Essler	Member of the Supervisory Board	less than a year	geen gegevens	geen gegevens

8.5yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van FYBD wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.5 jaar).

Formycon Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Formycon AG Appoints Colin Bond as Director

Formycon AG Announces Supervisory Board and Executive Changes

Formycon AG Announces Changes to Its Executive Board

Formycon AG, Annual General Meeting, Sep 27, 2021

Recent updates

Formycon AG Appoints Colin Bond as Director

Fresenius Kabi and Formycon Receives U.S. FDA Approval for Biosimilar Otulfi (ustekinumab-aauz)

Formycon AG to Report First Half, 2024 Results on Aug 13, 2024

Formycon AG to Report Q1, 2024 Results on May 08, 2024

Formycon AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

Formycon AG has completed a Follow-on Equity Offering in the amount of €82.840247 million.

Formycon AG to Report First Half, 2023 Results on Aug 30, 2023

Formycon Announces Submission of the Biologics License Application (Bla) for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration (Fda)

Full year 2022 earnings released: EPS: €2.62 (vs €1.22 loss in FY 2021)

Formycon AG has completed a Follow-on Equity Offering in the amount of €70.07 million.

Formycon AG Publishes Details of A Previously Undisclosed Pipeline Project – Fyb206 Is A Biosimilar Candidate for Keytruda (Pembrolizumab)

Formycon AG, Polpharma Biologics Group BV and Bioeq AG Announce European Commission Approval for FYB201/Ranivisio1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis2 (News with Additional Features)

Formycon Ag Announces EU-Approval of FYB201/Ranivisio A Biosimilar to Lucentis

Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara in Phase III Study

Formycon Announces FDA Approval of Fyb201/Cimerlitm1 (Ranibizumab-EQRN) as A Biosimilar Interchangeable with Lucentis®2

Formycon AG Announces Supervisory Board and Executive Changes

Formycon's Biosimilar for Lucentis (Ranibizumab), Receives CHMP Recommendation from EMA

Forecast breakeven date pushed back to 2023

Formycon AG Announces Changes to Its Executive Board

Formycon AG Announces Receipt of Market Authorization of from Medicines and Healthcare Products Regulatory Agency

Formycon AG Provides Revenue Guidance for the Year 2021

Formycon AG and Bioeq AG Announce Submits Biologics License Application for FYB201 to U.S. Food and Drug Administration

Formycon AG Provides Sales Guidance for the Fiscal Year 2021

Formycon Receives Approval for Early Action for COVID-19 Drug FYB207 as Part of a Grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy

Formycon Receives Positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and Assures GMP Manufacturing Capacities

Formycon AG, Annual General Meeting, Sep 27, 2021

Formycon's Scientific Collaboration Partners Present FYB207 Results At International Keystone Symposium

New 90-day high: €47.00

Formycon AG and Bioeq GmbH Announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara(R) (Ustekinumab)

Formycon AG and Bioeq AG Announce Biologics License Application Resubmission Strategy for Fyb201 Has Been Adjusted

Formycon AG to Report Q1, 2020 Results on Jun 22, 2020

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur